|
09 Jan 2020 |
Bayer and Evotec form new strategic alliance focusing on polycystic ovary syndrome
|
|
09 Jan 2020 |
Curis Announces Option and License Agreement with ImmuNext for the Development and Commercialization of Anti-VISTA Antibodies
|
|
09 Jan 2020 |
Altavant Sciences Acquires Onspira Therapeutics, Adding a Potentially Life-Saving Treatment for Post-Lung Transplant Patients to the Altavant Pipeline
|
|
09 Jan 2020 |
WuXi Biologics and Almirall Sign Strategic Collaboration Agreement for Multiple Bispecific Antibodies Targeting Dermatology Diseases
|
|
09 Jan 2020 |
SAB Biotherapeutics Announces Research Collaboration With CSL Behring
|
|
08 Jan 2020 |
Verastem Oncology Announces Global Licensing Agreement with Chugai Pharmaceutical Co., Ltd. to Develop and Commercialize RAF/MEK Inhibitor CH5126766
|
|
08 Jan 2020 |
Xencor and Gilead Enter License Agreement for Use of XmAb® Antibody Technologies in Investigational Agents for HIV
|
|
07 Jan 2020 |
Cytovia Therapeutics and the University of California, San Francisco enter into a partnership to develop precision gene-edited CAR-NK cell therapy
|
|
07 Jan 2020 |
Galecto and PharmAkea Merge to Create Strong Clinical-Stage Company Developing First-in-Class Therapeutics in Fibrosis and Cancer
|
|
07 Jan 2020 |
PhoreMost and Boehringer Ingelheim enter multi-project drug discovery collaboration
|
|
06 Jan 2020 |
Yisheng Biopharma and Tavotek Biotherapeutics Announce Strategic Research Alliance for Development of YS-ON-001/002 and Tavo-301/303 Combination Therapy for Cancer Treatment
|
|
06 Jan 2020 |
Merck Establishes Strategic Oncology Collaboration with Taiho and Astex
|
|
06 Jan 2020 |
GlycoMimetics and Apollomics Announce Exclusive Collaboration and License Agreement to Develop and Commercialize Uproleselan and GMI-1687 in Greater China
|
|
03 Jan 2020 |
Leap Therapeutics and BeiGene Announce Exclusive Option and License Agreement for DKN-01 and Leap Announces $27 Million Equity Financing
|
|
02 Jan 2020 |
Arena Pharmaceuticals and Beacon Discovery Expand Strategic Relationship Focusing on Multiple Immune and Inflammatory Targets
|
|
02 Jan 2020 |
Pulmatrix Announces Kinase Inhibitor Licensing Agreement with Lung Cancer Initiative at Johnson & Johnson
|
|
02 Jan 2020 |
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology Presence in China
|
|
30 Dec 2019 |
Milestone for Biopharmaceuticals in China
|
|
30 Dec 2019 |
Acceleron and Fulcrum Therapeutics Announce Pulmonary Research and Discovery Collaboration Agreement
|
|
27 Dec 2019 |
Astellas Strengthens Immuno-oncology Pipeline with Acquisition of Xyphos Biosciences, Inc.
|
|
24 Dec 2019 |
NewLink Genetics Announces Exclusive Worldwide License Agreement with Ellipses Pharma for Development of and Rights to Commercialization of NLG207
|
|
24 Dec 2019 |
Gilead and Eisai Enter Into Agreement in Japan for the Co-Promotion of the Investigational Rheumatoid Arthritis Therapy Filgotinib, Pending Regulatory Approval
|
|
23 Dec 2019 |
Sarepta Therapeutics Announces Partnership with Roche in Territories Outside the United States for its Investigational Micro-dystrophin Gene Therapy for Duchenne Muscular Dystrophy, SRP-9001
|
|
23 Dec 2019 |
Fortress Biotech Announces Exclusive Worldwide License Agreement With AstraZeneca and Cincinnati Children’s Hospital Medical Center to Develop a Novel Treatment for Select CNS Disorders
|
|
23 Dec 2019 |
Theravance Biopharma and Pfizer Inc. Enter Global License Agreement for Skin-Targeted, Locally-Acting Pan-Janus Kinase (JAK) Inhibitor Program
|
